Background Endometrial cancer is the most common gynecologic malignancy. The majority
of patients have disease confined to the uterus and have an excellent overall prognosis …

Hormonal therapy and chemotherapy play a major role in the management of advanced or
recurrent endometrial cancer. Progesterone therapy obtains overall response rates ranging …

OBJECTIVE: A phase II trial was performed to evaluate the efficacy and safety of the tyrosine
kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2, lapatinib, and to …

• In 2009, the International Federation of Gynecology and Obstetrics revised the staging
system for carcinomas of the endometrium; major changes include grouping stages IA and …

BACKGROUND: A phase II trial was performed to evaluate the efficacy and safety of gefitinib
in patients with persistent/recurrent endometrial cancer. METHODS: Women with …

Endometrial cancer is one of the most common gynecologic malignancies. In patients with
advanced or recurrent endometrial cancer survival is greatly diminished. Hormonal therapy …

Endometrial cancer (EC) is the most commonly diagnosed gynecologic malignancy.
Although early-stage EC is effectively treated surgically, commonly without adjuvant therapy …

Objective The article is to study the expressions of COX-2, VEGF-C, and EGFR in
endometrial carcinoma as well as its clinical significances. Materials and methods Clinical …

Endometrial cancer is the most common gynaecological cancer in western countries.
Radiotherapy remains the mainstay of postoperative management, but accumulating data …

OBJECTIVES: To discuss the novel agents which are being developed for the treatment of
advanced and recurrent endometrial carcinoma and to review other molecular targets that …